GALECTIN THERAPEUTICS INC. overview

...

...

Galectin Therapeutics Presentation Now Available for On-Demand Viewing PR Newswire NORCROSS, Ga., Feb. 6, 2017 Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation NORCROSS, Ga. , Feb. 6, 2017 /PRNewswire/ -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the February 2nd presentation from Peter G. Traber , M.D, President,...

NORCROSS, Ga., Feb. 01, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced it has generated sufficient financing to cover currently planned expenditures through 2017 and it remains on track to present top line data from its NASH-CX Phase 2 clinical trial by early December 2017. Through the sale of common stock via the Company’s At-The Market sales agreement, and previously announced private...

Life Sciences & Healthcare Investor Conference & Webinar: Nasdaq and OTCQX Companies Present February 2nd PR Newswire NEW YORK, Jan. 30, 2017 CEOs & CFOs share vision, answer questions live at VirtualInvestorsConferences.com NEW YORK , Jan. 30, 2017 /PRNewswire/ -- PR Newswire and BetterInvesting (NAIC) today announced the agenda for the upcoming VirtualInvestorConferences.com, the evergreen online investor conference series. Individual investors, institutional investors, advisors, and analysts...

Galectin Therapeutics to Webcast, Live, at VirtualInvestorConferences.com on February 2 PR Newswire NORCROSS, Ga., Jan. 30, 2017 The Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual VirtualInvestorConferences.com NORCROSS, Ga. , Jan. 30, 2017 /PRNewswire/ -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that Peter G. Traber , M.D, president, chief...

NORCROSS, Ga., Dec. 29, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced it has recently completed a private placement of its common stock, raising $3,000,000 in new funding. In a separate transaction, the Company also closed an additional sale of its Series B-3 preferred stock resulting in $1,008,000 of additional new proceeds. In the placement of common stock, one existing investor and a new...

NORCROSS, Ga., Dec. 08, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the Company will present a corporate update via live webcast immediately following the business portion of its 2016 Annual Meeting of Stockholders. Peter Traber, M.D., president, chief executive officer and chief medical officer, will provide an overview of the progress achieved over the past year, as well as the...